Liyuan Zheng's research while affiliated with Guangdong Medical University and other places

What is this page?


This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.

It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.

If you're a ResearchGate member, you can follow this page to keep up with this author's work.

If you are this author, and you don't want us to display this page anymore, please let us know.

Publications (3)


Establishment and characterization of the acquired oxaliplatin-resistant CRC cell line HCT8/L-OHP. A CCK8 assay to assess the IC50 of oxaliplatin-resistant CRC cells HCT8/L-OHP and parental HCT8 cells after treated with increasing concentrations of oxaliplatin treatment for 48 h. B The IC50 of oxaliplatin to HCT8 and HCT8/L-OHP cells were calculated from the inhibition curves. C P-gp protein expression in HCT8 and HCT8/L-OHP cells was determined by western blotting analysis. D Flow cytometry analysis measures the apoptosis in HCT8 and HCT8/L-OHP cells at 24 h after oxaliplatin treatment. Bar charts show the percentage of apoptosis E and surviving F cells, respectively, in both untreated and oxaliplatin-treated groups. Data are presented as the mean ± SD of three independent experiments. ***p < 0.001
Purine metabolism was upregulated in oxaliplatin-resistant HCT8/L-OHP cells. A PCA 3D score plot between HCT8 and HCT8/L-OHP groups. B Volcano plot of differential metabolites. C Bubble plots for KEGG metabolic pathway enrichment analysis of differential metabolites. D Hierarchical clustering analysis of differential metabolites involved in purine metabolism. E QPCR analysis of purine metabolic key enzyme genes in HCT8/L-OHP comparing to those in HCT8 cells. ACTB was used as the internal reference. F Western blotting analysis of IMPDH2 protein expression in HCT8 and HCT8/L-OHP cells. G Schematic diagram of purine metabolism. The red indicates that the metabolite is up-regulated, the blue indicates that the metabolite is down-regulated, while the gray indicates metabolite with no significant change. G-6-P Glucose-6-phosphate, R-5-P Ribose-5-phosphate, IMP Inosinic acid, XMP, Xanthylic acid; GMP, Guanosine monophosphate; dGMP, Deoxyguanosine monophosphate; AMP Adenosine monophosphate. Significance is indicated as ns  not significant, *p < 0.05, **p < 0.01, and ***p < 0.001
IMPDH2 expression is upregulated in CRC patients and is associated with multiple drug resistance. A IMPDH2 expression in various types of cancer in the TIMER database. B The mRNA expression of IMPDH2 in 24 matched CRC and adjacent noncancerous samples from the GSE10950. The protein expression of IMPDH2 in CRC based on sample types (C), individual cancer stages D and histological subtypes E from CPTAC. F The IMPDH2 protein expression from HPA database. GSEA was performed to showing a significant association between the IMPDH2 expression and the PURINE_METABOLISM G and MULTIPLE-DRUG-RESISTANCE H. **p < 0.01, and ***p < 0.001
IMPDH2 expression is associated with CRC cells sensitivity to oxaliplatin. A and B The endogenous expression of IMPDH2 in four CRC cell lines, SW620, RKO, HCT116 and HCT8, was determined by qPCR and western blotting analysis. The mRNA and protein expression of IMPDH2 in HCT8 C and D and SW620 E and F in response to oxaliplatin treatment were determined by qPCR and western blotting analysis. G Flow cytometric analysis was performed to analyse the apoptotic rate in HCT8 and SW620 cells treated with increasing concentrations of oxaliplatin at 24 h. The histograms show the percentage of apoptosis H and surviving I cells, respectively, in both untreated and oxaliplatin-treated groups. Data are presented as the mean ± SD of three independent experiments. ns  not significant, ***p < 0.001
IMPDH2 regulates cell apoptosis of CRC in response to oxaliplatin. A and B Overexpression of IMPDH2 was confirmed at the mRNA and protein level in HCT8 cells by qPCR and western blotting. C Comparison of apoptosis induction between vector and IMPDH2-overexpression cells in HCT8 after oxaliplatin treatment was carried out by flow cytometry analysis. Bar charts show the percentage of apoptotic and surviving cells, respectively. D and E The mRNA and protein expression levels of stable knockdown IMPDH2 in HCT8/L-OHP cells were quantified by qPCR and western blotting analysis. F Flow cytometry analysis was performed to analyse the apoptotic rate in shNC and shIMPDH2 HCT8/L-OHP cells after oxaliplatin treatment. G Western blotting analysis of apoptotic proteins expression was carried out between vector and IMPDH2-overexpression HCT8 cells after oxaliplatin treatment. H Western blotting analysis was performed to detect the expression of apoptotic proteins in shNC or IMPDH2-knockdown HCT8/L-OHP cells after oxaliplatin treatment. I The apoptotic rate was analysed after GMP and/or oxaliplatin treatment compared with that of untreated cells for 24 h by flow cytometry analysis in HCT8 cells. J The apoptotic rate was analysed after MPA and/or oxaliplatin treatment compared with that of untreated cells for 24 h by flow cytosmetry analysis in HCT8/L-OHP cells. Data are presented as the mean ± SD of three independent experiments. **p < 0.01, and ***p < 0.001

+2

Wnt/β-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer
  • Article
  • Full-text available

February 2024

·

5 Reads

Journal of Translational Medicine

Yuting Huang

·

Szehoi Chan

·

Shuna Chen

·

[...]

·

Bo Zhang

Background Oxaliplatin resistance usually leads to therapeutic failure and poor prognosis in colorectal cancer (CRC), while the underlying mechanisms are not yet fully understood. Metabolic reprogramming is strongly linked to drug resistance, however, the role and mechanism of metabolic reprogramming in oxaliplatin resistance remain unclear. Here, we aim to explore the functions and mechanisms of purine metabolism on the oxaliplatin-induced apoptosis of CRC. Methods An oxaliplatin-resistant CRC cell line was generated, and untargeted metabolomics analysis was conducted. The inosine 5ʹ-monophosphate dehydrogenase type II (IMPDH2) expression in CRC cell lines was determined by quantitative real-time polymerase chain reaction (qPCR) and western blotting analysis. The effects of IMPDH2 overexpression, knockdown and pharmacological inhibition on oxaliplatin resistance in CRC were assessed by flow cytometry analysis of cell apoptosis in vivo and in vitro. Results Metabolic analysis revealed that the levels of purine metabolites, especially guanosine monophosphate (GMP), were markedly elevated in oxaliplatin-resistant CRC cells. The accumulation of purine metabolites mainly arose from the upregulation of IMPDH2 expression. Gene set enrichment analysis (GSEA) indicated high IMPDH2 expression in CRC correlates with PURINE_METABOLISM and MULTIPLE-DRUG-RESISTANCE pathways. CRC cells with higher IMPDH2 expression were more resistant to oxaliplatin-induced apoptosis. Overexpression of IMPDH2 in CRC cells resulted in reduced cell death upon treatment with oxaliplatin, whereas knockdown of IMPDH2 led to increased sensitivity to oxaliplatin through influencing the activation of the Caspase 7/8/9 and PARP1 proteins on cell apoptosis. Targeted inhibition of IMPDH2 by mycophenolic acid (MPA) or mycophenolate mofetil (MMF) enhanced cell apoptosis in vitro and decreased in vivo tumour burden when combined with oxaliplatin treatment. Mechanistically, the Wnt/β-catenin signalling was hyperactivated in oxaliplatin-resistant CRC cells, and a reciprocal positive regulatory mechanism existed between Wnt/β-catenin and IMPDH2. Blocking the Wnt/β-catenin pathway could resensitize resistant cells to oxaliplatin, which could be restored by the addition of GMP. Conclusions IMPDH2 is a predictive biomarker and therapeutic target for oxaliplatin resistance in CRC.

Download
Share

Oscillating Fluid Flow Activated Osteocyte Lysate-Based Hydrogel for Regulating Osteoblast/Osteoclast Homeostasis to Enhance Bone Repair

April 2023

·

45 Reads

·

5 Citations

Advanced Science

Advanced Science

As major regulators on bone formation/resorption in response to mechanical stimuli, osteocytes have shown great promise for restoring bone injury. However, due to the unmanageable and unabiding cell functions in unloading or diseased environments, the efficacy of osteogenic induction by osteocytes has been enormously limited. Herein, a facile method of oscillating fluid flow (OFF) loading for cell culture is reported, which enables osteocytes to initiate only osteogenesis and not the osteolysis process. After OFF loading, multiple and sufficient soluble mediators are produced in osteocytes, and the collected osteocyte lysates invariably induce robust osteoblastic differentiation and proliferation while restraining osteoclast generation and activity under unloading or pathological conditions. Mechanistic studies confirm that elevated glycolysis and activation of the ERK1/2 and Wnt/β-catenin pathways are the major contributors to the initiation of osteoinduction functions induced by osteocytes. Moreover, an osteocyte lysate-based hydrogel is designed to establish a stockpile of "active osteocytes" to sustainably deliver bioactive proteins, resulting in accelerated healing through regulation of endogenous osteoblast/osteoclast homeostasis.


Biomimetic Microcavity Interface for Label-free Capture of Pathogens in Fluid Bloodstream by Vortical Crossflow Filtration

September 2021

·

30 Reads

·

1 Citation

Nanoscale

Bacterial sepsis is a lethal disease triggered by microbial pathogens. The blood pathogen load is a major contributor to both disease severity and mortality in patients with sepsis blood. Therefore, it is crucial to reduce the load of pathogens, in particular the drug-resistant pathogens. In this work, inspired by the crossflow filtration mechanism in suspension-feeding fish, we developed a biomimetic microcavity interface to mimic a porous gill-raker surface as a blood-cleansing dialyzer for sepsis therapy, which can rapidly, safely and efficiently clear bacteria from the fluidic blood. The microcavity interface consists of microcavity arrays, the innerface of which contains nanowire forests. By precisely controlling the pore size of the microcavity and directing the axial travel of the fluid, the bacteria can be isolated from the whole blood without disturbing any blood components or blocking the blood cell transportation. In addition, the three-dimensional nanowire forests assist in the formation of vortices with reduced blood flow velocity and increased resistance to bacterial deposition in situ. Functional modification is not required to recognize the bacteria specifically in our designed dialyzer. Moreover, the microcavity interface clears over 95% bacteria from a fluid blood sample without inducing protein adsorption or complement and platelet activation when contacting the fluid blood. The study supports this biomimetic microcavity interface to be a promising extracorporeal blood-cleansing device in clinical settings.

Citations (1)


... This fluid flow leads to a strain-driven interstitial fluid movement through the canaliculi and along the osteocyte processes, which is sensed and transduced by the osteocytes [51]. This interstitial fluid flow stimulates signaling molecule production by osteocytes that stimulate osteoclastic bone resorption, or osteoblastic bone formation [14,52]. Mechanotransduction then comprises the translation of canalicular flow by osteocytes into cell signals that recruit osteoclasts and osteoblasts [44•, 45]. ...

Reference:

Osteocyte Mechanotransduction in Orthodontic Tooth Movement
Oscillating Fluid Flow Activated Osteocyte Lysate-Based Hydrogel for Regulating Osteoblast/Osteoclast Homeostasis to Enhance Bone Repair
Advanced Science

Advanced Science